Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiroshi Morinaga has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • Hitoshi Sugiyama

    Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan

    6 shared publications
  • Jun Wada

    Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

    4 shared publications
  • Haruhito Adam Uchida

    Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

    3 shared publications
  • Akira Shimizu

    Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan

    2 shared publications
  • Katsuyuki Tanabe

    Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

    2 shared publications
  • Keiko Tanaka

    Department of Nephrology, Rheumatology, Endocrinology and Metabolism Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan

    2 shared publications

Latest Publications

  • Open Access

    Demographic and clinical characteristics of rapidly progressive glomerulonephritis in renal vasculitis in the Japan renal biopsy registry

    by Hiroshi Morinaga, Hitoshi Sugiyama, Joichi Usui, Yayoi Ogawa, Naotake Tsuboi, Hiroshi Sato, Hitoshi Yokoyama, Akira Shimizu, Shoichi Maruyama, Kunihiro Yamagata, et al.

  • Morphological subtypes and clinicopathological features of podocyte infolding glomerulopathy: retrospective nationwide Japanese cohort study of 93 cases

    by Kazuhiro Takeuchi, Akiko Mii, Ritsuko Katafuchi, Yoshihide Fujigaki, Shiko Honma, Takamasa Iwakura, Mineaki Kitamura, Yuta Matsukuma, Makoto Abe, Ryoko Sakaguchi, et al.

    Background Podocyte infolding glomerulopathy (PIG) is a rare glomerular disease, with case reports and cohort studies lacking clear morphological diagnostic criteria. We aimed to establish transmission electron microscopy (TEM)–based diagnostic criteria for PIG and classify its morphological subtypes. Methods This retrospective nationwide cohort study was conducted by the PIG Working Group of the Japanese Society of Nephrology. Clinical data and TEM findings were collected from patients diagnosed with or suspected of PIG at 69 institutions across Japan between 1991–2025. PIG was defined by TEM as podocyte infolding exceeding half the glomerular basement membrane (GBM) thickness at two or more sites within a single capillary loop or the presence of microspheres or microtubules within the GBM. Cases were classified into morphological subtypes, and their clinical characteristics were analyzed. Results Among 103 registered cases, 93 met diagnostic criteria. Four morphological subtypes were identified: Type A, primary podocyte infolding without prominent microspheres or microtubules (n = 21); Type B, predominant microspheres (n = 34); Type C, microtubules with or without microspheres (n = 38); and Type D, dense clusters of microspheres (n = 10). Types B and C were more common in younger females and frequently associated with systemic lupus erythematosus (58% and 71%, respectively), whereas Types A and D occurred mainly in older males and were not associated with SLE. Conclusions We established TEM-based diagnostic criteria for PIG and identified four morphological subtypes, suggesting two clinicopathological phenotypes: SLE-associated (B and C) and non–SLE-associated (A and D).

  • Open Access

    Late-onset renal variant Fabry disease with R112H mutation and mild increase in plasma globotriaosylsphingosine: a case report

    by Keiko Tanaka, Hitoshi Sugiyama, Hiroshi Morinaga, Akifumi Onishi, Katsuyuki Tanabe, Haruhito A. Uchida, Hiroki Maruyama, Jun Wada

    Fabry disease (FD) is an X-linked disorder resulting in a deficiency of α-galactosidase A (GLA) activity. The R112H mutation of GLA is relatively common in Japanese FD patients, characterized by a late-onset phenotype, almost normal to mild lyso-Gb3 elevation, and mild clinical symptoms, despite low GLA activity. This is due to the structural features of the R112H GLA protein. We herein report the case of a 42-year-old male patient with late-onset FD with a R112H mutation. The patient exhibited only renal involvement with no other organ damage and was successfully treated with galactosidase beta and subsequent migalastat for approximately 10 years. Especially, migalastat was clinically effective in normalizing plasma lyso-Gb3 levels and inhibiting the progression of renal damage associated with FD. Therefore, the use of migalastat in the FD patients with R112H mutation is highly recommended based on this case report.


  • Open Access

    The Effect of Medical Cooperation in the CKD Patients: 10-Year Multicenter Cohort Study

    by Yasuhiro Onishi, Haruhito A. Uchida, Yohei Maeshima, Yuka Okuyama, Nozomu Otaka, Haruyo Ujike, Keiko Tanaka, Hidemi Takeuchi, Kenji Tsuji, Masashi Kitagawa, et al.

    Introduction: While chronic kidney disease (CKD) is one of the most important contributors to mortality from non-communicable diseases, the number of nephrologists is limited worldwide. Medical cooperation is a system of cooperation between primary care physicians and nephrological institutions, consisting of nephrologists and multidisciplinary care teams. Although it has been reported that multidisciplinary care teams contribute to the prevention of worsening renal functions and cardiovascular events, there are few studies on the effect of a medical cooperation system. Methods: We aimed to evaluate the effect of medical cooperation on all-cause mortality and renal prognosis in patients with CKD. One hundred and sixty-eight patients who visited the one hundred and sixty-three clinics and seven general hospitals of Okayama city were recruited between December 2009 and September 2016, and one hundred twenty-three patients were classified into a medical cooperation group. The outcome was defined as the incidence of all-cause mortality, or renal composite outcome (end-stage renal disease or 50% eGFR decline). We evaluated the effects on renal composite outcome and pre-ESRD mortality while incorporating the competing risk for the alternate outcome into a Fine–Gray subdistribution hazard model. Results: The medical cooperation group had more patients with glomerulonephritis (35.0% vs. 2.2%) and less nephrosclerosis (35.0% vs. 64.5%) than the primary care group. Throughout the follow-up period of 5.59 ± 2.78 years, 23 participants (13.7%) died, 41 participants (24.4%) reached 50% decline in eGFR, and 37 participants (22.0%) developed end-stage renal disease (ESRD). All-cause mortality was significantly reduced by medical cooperation (sHR 0.297, 95% CI 0.105–0.835, p = 0.021). However, there was a significant association between medical cooperation and CKD progression (sHR 3.069, 95% CI 1.225–7.687, p = 0.017). Conclusion: We evaluated mortality and ESRD using a CKD cohort with a long-term observation period and concluded that medical cooperation might be expected to influence the quality of medical care in the patients with CKD.


  • Open Access

    Serum sCD40L and IL-31 in Association with Early Phase of IgA Nephropathy

    by Keiko Tanaka, Hitoshi Sugiyama, Hiroshi Morinaga, Masashi Kitagawa, Yuzuki Kano, Yasuhiro Onishi, Koki Mise, Katsuyuki Tanabe, Haruhito A. Uchida, Jun Wada

    Background: IgA nephropathy (IgAN) is a major cause of chronic glomerulonephritis worldwide. T cell dysregulation has been reported to contribute to the pathogenesis of IgAN. Methods We measured a broad range of Th1, Th2 and Th17 cytokines in the serum of IgAN patients. We searched for significant cytokines, which were associated with clinical parameters and histological scores in IgAN patients. Results: Among 15 cytokines, the levels of soluble CD40L (sCD40L) and IL-31 were higher in IgAN patients and were significantly associated with a higher estimated glomerular filtration rate (eGFR), a lower urinary protein to creatinine ratio (UPCR), and milder tubulointerstitial lesions (i.e., the early phase of IgAN). Multivariate analysis revealed that serum sCD40L was an independent determinant of a lower UPCR after adjustment for age, eGFR, and mean blood pressure (MBP). CD40, a receptor of sCD40L, has been reported to be upregulated on mesangial cells in IgAN. The sCD40L/CD40 interaction may directly induce inflammation in mesangial areas and may therefore be involved in the development of IgAN. Conclusions: The present study demonstrated the significance of serum sCD40L and IL-31 in the early phase of IgAN. Serum sCD40L may be a marker of the beginning of inflammation in IgAN.


  • Open Access

    Serum cystatin C is an independent biomarker associated with the renal resistive index in patients with chronic kidney disease

    by Ayu Ogawa-Akiyama, Hitoshi Sugiyama, Masashi Kitagawa, Keiko Tanaka, Akifumi Onishi, Toshio Yamanari, Hiroshi Morinaga, Haruhito Adam Uchida, Kazufumi Nakamura, Hiroshi Ito, et al.

    Cystatin C is a cysteine protease inhibitor that is produced by nearly all human cells. The serum level of cystatin C is a stronger predictor of the renal outcome and the risk of cardiovascular events than the creatinine level. The resistive index (RI) on renal Doppler ultrasonography is a good indicator of vascular resistance as well as the renal outcomes in patients with chronic kidney disease (CKD). However, it is unclear whether serum cystatin C is associated with signs of vascular dysfunction, such as the renal RI. We measured the serum cystatin C levels in 101 CKD patients and investigated the relationships between cystatin C and markers of vascular dysfunction, including the renal RI, ankle-brachial pulse wave velocity (baPWV), intima-media thickness (IMT), and cardiac function. The renal RI was significantly correlated with the serum cystatin C level (p < 0.0001, r = 0.6920). The serum cystatin C level was found to be a significant determinant of the renal RI (p < 0.0001), but not the baPWV, in a multivariate regression analysis. The multivariate odds ratio of the serum cystatin C level for a renal RI of more than 0.66 was statistically significant (2.92, p = 0.0106). The area under the receiver-operating characteristic curve comparing the sensitivity and specificity of cystatin C for predicting an RI of more than 0.66 was 0.882 (cutoff value: 2.04 mg/L). In conclusion, the serum cystatin C level is an independent biomarker associated with the renal RI in patients with CKD.


  • The frequency of Fabry disease with the E66Q variant in the ?-galactosidase A gene in Japanese dialysis patients: a case report and a literature review

    by Y. Kikumoto, H. Sugiyama, H. Morinaga, T. Inoue, K. Takiue, M. Kitagawa, D. Saito, Y. Takatori, M. Kinomura, S. Kitamura, et al.

    Fabry disease (FD) is an Xlinked disorder resulting in a deficiency in α-galactosidase A (α-Gal) activity. FD is one of the causes of progressive renal dysfunction, but its diagnosis is often delayed or missed completely. We herein report the case of a 70-year-old male who had been receiving hemodialysis (HD) for 23 y who was diagnosed with FD after his participation in a screening program for plasma α-Gal activity for 892 HD patients. He had a low plasma α-Gal activity level and was demonstrated to have an E66Q mutation in exon 2 of the α-Gal gene. One of his daughters had the same mutation. The proband died due to aspiration pneumonia before receiving enzyme replacement therapy. We reviewed previous studies and found E66Q mutation in 36% of Japanese FD patients on HD including the present case. The clinical characteristics of E66Q variant are also discussed.


  • Open Access

    Fabry Disease Exhibiting Recurrent Stroke and Persistent Inflammation

    by Yoko Kikumoto, Yasufumi Kai, Hiroshi Morinaga, Mutsunori Iga-Murahashi, Mikitaro Matsuyama, Takashi Sasaki, Hiroki Maruyama, Masaaki Shimotori, Hirofumi Makino, Hitoshi Sugiyama, et al.

    We describe two cases of Fabry disease in non-blood-related Japanese men, manifesting recurrent stroke even after the start of enzyme replacement therapy. Both exhibited chronic inflammation and ocular involvement with elevated levels of serum C reactive protein prior to the onset of stroke. We, therefore, suggest the association among persistent inflammation, ocular involvement and recurrent stroke in a certain subset of Fabry disease patients. Both cases received enzyme replacement therapy with no improvement in inflammatory signs or laboratory data. These cases suggest that Fabry disease should be considered in young patients with cryptogenic stroke or CNS manifestations and fever of unknown origin.